On August 25, 2023, Decibel Therapeutics, Inc. announced that the U.S. Food and Drug Administration had granted fast track designation for DB-OTO, the Company?s lead gene therapy product candidate for congenital hearing loss caused by mutations of the otoferlin gene.
Decibel Therapeutics, Inc.
Equities
DBTX
US24343R1068
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+44.48% | 55.07B | |
+43.91% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |